Engineered immune cells take aim at stubborn blood disorder
NCT ID NCT07689604
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This early-phase trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) that has not responded to standard treatments. AIHA is a condition where the immune system mistakenly destroys red blood cells, causing anemia. META 10-19 uses a patient's own immune cells (T-cells) that are modified in a lab to target and eliminate the faulty immune cells causing the destruction. The study will enroll 18 adults aged 18 to 75 and primarily assess safety, while also measuring how well the therapy controls the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- META 10-19 (metabolically armed autologous CD19 CAR T-cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat autoimmune hemolytic anemia, potentially reducing the need for ongoing medications.
- What could go wrong
- This is a very early (Phase 1) trial with only 18 participants, so safety and effectiveness are not yet established. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New study aims to unlock the secrets of Children's rare blood diseases
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
- Experimental CAR-T therapy takes on stubborn blood disorder
- New drug combo aims to tame stubborn blood disorders